Treatment Algorithms Secondary Prevention - Managing Post-ACS Patients

A number of therapies have been shown to reduce the risk of death and subsequent cardiovascular events in post-ACS patients. Despite its highly competitive nature, the size of the patient population continues to attract R&D investment. However, key questions remain, including the optimal combination of therapies and how new therapies can penetrate this well-served market 

Scope:

* Identification of factors that deter physicians from prescribing all recommended therapies and analysis of the order in which drug classes are added 

* Discussion of the most effective ways to improve physician and patient compliance within the post-ACS patient population 

* Identification of the key unmet needs that remain and an analysis of the potential for new drugs for this indication 

* Recognition of the companies that are best placed to exploit the opportunities that exist in this market 

Report Highlights:

Although improvements have been made over recent years, particularly with the prescription of statins, secondary prevention therapies remain underused, despite recommendations for aggressive therapy 

The most common reasons for failure to prescribe aggressive therapy are that patients do not have high blood pressure/cholesterol levels and concerns about patient compliance. This presents opportunities for companies to promote the benefits of their drugs beyond blood pressure/lipid control and to support initiatives aimed at improving compliance 

Although developments that improve patient compliance, such as single-pill combinations, better-tolerated drugs and more efficacious therapies would be beneficial, the greatest advance would be the development of therapies that are able to reverse the atherosclerotic disease process and repair myocardial damage that occurs post infarction 

Reasons to Purchase:

* Assess what determines physicians prescribing patterns and in which order secondary prevention therapies are added to a patient’s treatment 

* Evaluate what deters physicians from prescribing all recommended therapies and identify opportunities for increasing market size and market share 

* Understand what new therapies need to demonstrate in order to penetrate this highly competitive market 

Publisher: Datamonitor Cardiovascular Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Cardiovascular.html#a8